产品描述
Revusiran (ALN-TTRSC) is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran can be used for transthyretin (TTR)-mediated amyloidosis research.
体外活性
Revusiran is a chemically synthesized double-stranded siRNA that is covalently linked at the 3′-end of its sense strand to a ligand containing three GalNAc residues. Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors[1].
体内活性
There are no effects on cardiovascular or respiratory function in monkeys after single doses of up to 100 mg/kg. No neurological effects weare noted in monkeys in repeat-dose studies up to 300 mg/kg. Revusiran is well tolerated in repeat-dose mouse (weekly doses) and rat and monkey (five daily doses followed by weekly doses) toxicity studies[1].
Cas No.
1438322-82-7
别名
ALN-TTRSC;Revusiran
储存和溶解度
(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years